
Sanofi Bets More Than $1.8 Billion in Biobucks on AI-Developed Bispecifics
Sanofi continues to plant its artificial intelligence roots, signing a licensing deal potentially worth more than $1.8 billion with Earendil Labs for two bispecific antibodies. Earendil, a Delaware-based AI research and development company focused on …